• Featured Product
  • KD/KO Validated

AlaRS Polyclonal antibody

AlaRS Polyclonal Antibody for WB, IP, IF, IHC, ELISA

Host / Isotype

Rabbit / IgG







Cat no : 17394-1-AP


AARS, Alanine tRNA ligase, alanyl tRNA synthetase, AlaRS

Tested Applications

Positive WB detected inHepG2 cells, Jurkat cells
Positive IP detected inHepG2 cells
Positive IHC detected inhuman liver tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inHepG2 cells

Recommended dilution

Western Blot (WB)WB : 1:500-1:3000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)IHC : 1:20-1:200
Immunofluorescence (IF)IF : 1:200-1:800
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

17394-1-AP targets AlaRS in WB, IP, IF, IHC, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen AlaRS fusion protein Ag11294
Full Name alanyl-tRNA synthetase
Calculated Molecular Weight 968 aa, 107 kDa
Observed Molecular Weight 107 kDa
GenBank Accession NumberBC011451
Gene Symbol AARS
Gene ID (NCBI) 16
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

AARS(alanyl-tRNA synthetase) is also named as AlaRS(alanine tRNA ligase 1, cytoplasmic), renal carcinoma antigen NY-REN-42 and belongs to the class-II aminoacyl-tRNA synthetase family. It can interpret the RNA code and attach specific aminoacids to the tRNAs that contain the cognate trinucleotide anticodons. AARS consists of three domains: the N-terminal catalytic domain, the editing domain and the C-terminal C-Ala domain. The editing domain removes incorrectly charged amino acids, while the C-Ala domain, along with tRNA(Ala), serves as a bridge to cooperatively bring together the editing and aminoacylation centers thus stimulating deacylation of misacylated tRNAs(PMID:19661429).


Product Specific Protocols
WB protocol for AlaRS antibody 17394-1-APDownload protocol
IHC protocol for AlaRS antibody 17394-1-APDownload protocol
IF protocol for AlaRS antibody 17394-1-APDownload protocol
IP protocol for AlaRS antibody 17394-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Nat Commun

Comprehensive proteogenomic characterization of early duodenal cancer reveals the carcinogenesis tracks of different subtypes

Authors - Lingling Li